SAN DIEGO, Oct. 19, 2011 /PRNewswire/ -- The National Institute of Cancer (INCan), one of the best-equipped oncologic centers in Latin America, is the first to offer Positron Emission Mammography (PEM) to the residents of Mexico. PEM is the breast application of the Naviscan high-resolution PET scanner that shows the location as well as the metabolic phase of a lesion. It is the only FDA-cleared 3D Molecular Breast Imaging (MBI) device on the market.
The Naviscan PEM scanner is compact, mobile and easy-to-use for precisely characterizing breast cancer, enhancing surgical planning, monitoring patient response to chemotherapy and evaluating suspected recurrence. It is designed to show the metabolic phase of a lesion allowing for early breast cancer diagnosis and assisting physicians in making optimal care decisions by providing an ability to distinguish between benign and malignant lesions - what researchers term "specificity."
"With the arrival of PEM to the National Institute of Cancer in Mexico, we are offering our patients a diagnostic tool that will allow us to more accurately localize lesions as well as characterize them at a much earlier stage, with which we expect to reduce the harm that cancer causes our population," said Dr. Enrique Estrada-Lobato, Chairman of the Nuclear Medicine and Molecular Imaging Department of the National Institute of Cancer in Mexico.
"INCan's adoption of PEM is an outstanding validation of our technology and the center's dedication to providing patients with the best breast cancer care available. Naviscan is proud to partner with this center to provide the latest technological advances in breast cancer care to the women of Mexico," said Paul J. Mirabella, Chairman and CEO, Naviscan, Inc.
About Naviscan, Inc.
Naviscan, founded in 1995, develops and markets compact, high-resolution PET scanners intended to provide organ-specific molecular imaging and guide radiological and surgical procedures. The Naviscan PET scanner is currently installed and available in breast and imaging centers throughout the U.S. and other parts of the world. The Company is headquartered in San Diego, California and is the first to obtain FDA-clearance and CE Mark for a high-resolution PET scanner designed to image small body parts and for breast biopsy image guidance. For more information, call 1.858.587.3641 or visit www.naviscan.com
About the Instituto de Cancerologia
The Institute has achieved international recognition for its participation with institutions such as the American Society of Clinical Oncology (ASCO), the International Union Against Cancer (UICC), the University of Texas MD Anderson Cancer Center (UTMDACC), and the National Cancer Institute (NCI) of the National Institutes of Health (NIH) in the U.S. INCan is the coordinator of 25 State Cancer Centers (CEC) in Mexico, thus offering a unique possibility for designing common programs and strategies for better cancer control of a national character, and for achieving an impact at the national level on improving cancer prevention and early detection, reducing the morbi-morbility of cancer in Mexico.
For more information, including images, videos, quotes and links, please visit the social media news release (SMNR) at http://pitch.pe/181368
|SOURCE Naviscan, Inc.|
Copyright©2010 PR Newswire.
All rights reserved